Patents Assigned to INSITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
-
Patent number: 11820813Abstract: The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.Type: GrantFiled: August 17, 2020Date of Patent: November 21, 2023Assignees: INSERM (INSITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTESInventor: Patricia Forgez
-
Patent number: 11541131Abstract: The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.Type: GrantFiled: March 9, 2018Date of Patent: January 3, 2023Assignees: GENETHON, UNIVERSITE D'EVRY VAL D'ESSONNE, INSITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, SORBONNE UNIVERSITÉInventors: Federico Mingozzi, Giuseppe Ronzitti, Patrice Vidal
-
Patent number: 10858452Abstract: The present invention relates to specific interleukin-15 (IL-15) antagonist polypeptides and uses thereof for the treatment of inflammatory and auto-immune diseases. In particular, the present invention relates to a specific interleukin-15 (IL-15) antagonist polypeptide comprising i) a IL15-Ralpha sushi-containing polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence of SEQ ID NO:1 ii) a linker and iii) an IL-polypeptide comprising the amino acid sequence having at least at least 80% of identity with the amino acid sequence of SEQ ID NO:4 provided that the glutamine (Q) residue at position 108 is mutated.Type: GrantFiled: September 15, 2016Date of Patent: December 8, 2020Assignees: Insitut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes, Universite d'Angers, Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de NantesInventors: Erwan Mortier, Dihia Meghnem, Sebastien Morisseau, Yannick Jacques
-
Patent number: 10697965Abstract: The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3? in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3? antagonist or a compound which is a DNMT3A/ISGF3? gene expression inhibitor for use in the treatment and prevention of cancer.Type: GrantFiled: March 1, 2016Date of Patent: June 30, 2020Assignees: INSERM (INSITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, UNIVERSITE D'ANGERS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Pierre-Francois Cartron, Mathilde Cheray, Francois Valette
-
Patent number: 9889193Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumor or cancer conditions, and for the preparation of agents or compositions for such treatment.Type: GrantFiled: January 20, 2014Date of Patent: February 13, 2018Assignees: CENTRE NATIONAL DE LA RECHERCHE SCENTIFIQUE (CNRS), INSITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR, UNIVERSITE DE NANTESInventors: Frédéric Tangy, Marc Gregoire, Jean-François Fonteneau, Jean-Baptiste Guillerme, Chantal Combredet
-
Patent number: 9534036Abstract: The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool.Type: GrantFiled: March 15, 2013Date of Patent: January 3, 2017Assignees: Insitut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot—Paris 7, Universite Paris 13—Paris Nord, Assistance Publique—Hopitaux de ParisInventors: Giuseppina Caligiuri, Antonino Nicoletti
-
Patent number: 9340819Abstract: The present invention relates to a method for detecting the presence of carbapenemase-producing bacteria in a sample, said method comprising the steps of: a) performing cell lysis on a test sample in order to obtain an enzymatic suspension; b) reacting a fraction of the enzymatic suspension obtained in step a) with a reagent kit, said reagent kit comprising —a carbapenemase substrate selected from the group consisting of carbapenems and cephamycins, —a pH color indicator which will change color when the pH of the reaction mixture is comprised between 6.4 and 8.4, wherein a color change after step b) indicates the presence of carbapenemase-producing bacteria in the test sample. The invention also relates to a reagent kit, to a microtiter plate and to their uses in detecting the presence of carbapenemase producers in a test sample.Type: GrantFiled: June 21, 2012Date of Patent: May 17, 2016Assignees: INSERM (INSITUT NATIONAL de la SANTE ET de la RECHERCHE MEDICALE), ASSISTANCE PUBLIQUE HOPITAUX de PARIS, UNIVERSITE PARIS SUD (PARIS 11)Inventors: Laurent Dortet, Patrice Nordmann, Laurent Poirel
-
Publication number: 20160051832Abstract: A medical device (1) comprising a flexible light source wherein said flexible light source comprises two or more individually manageable areas (2, 3, 4) of light emission and wherein each area (2, 3, 4) comprises a light diffuser textile comprising optical fibres (10) providing side diffusion of a light, method for its manufacture and medical uses.Type: ApplicationFiled: March 21, 2014Publication date: February 25, 2016Applicant: INSERM (insitut National de la sante et de la Recherche MedicaleInventor: Serge Mordon
-
Patent number: 8785604Abstract: The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.Type: GrantFiled: February 16, 2011Date of Patent: July 22, 2014Assignees: Effimune, Insitut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Caroline Mary, Nicolas Poirier, Bernard Vanhove
-
Publication number: 20140148363Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo.Type: ApplicationFiled: January 30, 2014Publication date: May 29, 2014Applicant: Insitut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Samir Hamamah, John De Vos, Said Assou
-
Patent number: 7132513Abstract: The invention concerns a ligand comprising wherein n is an integer from 1 to 5, X represents —NO2, —NH2, —NCS, —NHCOCH2-Z. NHCO—W—COCNHS, —NH-Q, —NHCS-Q, —NHCOCH2-Q, or —NHCO(CH2)m ?-Q where Q is an hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, Y is CO2H or PO3H2 W is —(CH2)m— m is an integer from 1 to 10.Type: GrantFiled: March 9, 2001Date of Patent: November 7, 2006Assignees: European Community, INSERM Insitut National de la Santé et de la Recherche MédicaleInventors: Ali Ouadi, Jean-François Gestin, Christos Apostolidis